DK1441723T3 - Anvendelse af irbesartan til fremstilling af lægemidler til forebyggelse eller behandling af pulmonal hypertension - Google Patents

Anvendelse af irbesartan til fremstilling af lægemidler til forebyggelse eller behandling af pulmonal hypertension

Info

Publication number
DK1441723T3
DK1441723T3 DK02785535T DK02785535T DK1441723T3 DK 1441723 T3 DK1441723 T3 DK 1441723T3 DK 02785535 T DK02785535 T DK 02785535T DK 02785535 T DK02785535 T DK 02785535T DK 1441723 T3 DK1441723 T3 DK 1441723T3
Authority
DK
Denmark
Prior art keywords
irbesartan
drugs
prevention
manufacture
treatment
Prior art date
Application number
DK02785535T
Other languages
English (en)
Inventor
Sylvie Cosnier-Pucheu
Dino Nisato
Alain Roccon
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of DK1441723T3 publication Critical patent/DK1441723T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DK02785535T 2001-10-26 2002-10-09 Anvendelse af irbesartan til fremstilling af lægemidler til forebyggelse eller behandling af pulmonal hypertension DK1441723T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0113936A FR2831446B1 (fr) 2001-10-26 2001-10-26 Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
PCT/FR2002/003439 WO2003035062A1 (fr) 2001-10-26 2002-10-09 Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire

Publications (1)

Publication Number Publication Date
DK1441723T3 true DK1441723T3 (da) 2007-09-10

Family

ID=8868812

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02785535T DK1441723T3 (da) 2001-10-26 2002-10-09 Anvendelse af irbesartan til fremstilling af lægemidler til forebyggelse eller behandling af pulmonal hypertension

Country Status (24)

Country Link
US (2) US20040242567A1 (da)
EP (1) EP1441723B1 (da)
JP (1) JP4542777B2 (da)
CN (1) CN100418526C (da)
AT (1) ATE361071T1 (da)
AU (1) AU2002350832B2 (da)
BR (1) BR0213479A (da)
CA (1) CA2461625C (da)
CY (1) CY1106746T1 (da)
DE (1) DE60219940T2 (da)
DK (1) DK1441723T3 (da)
EA (1) EA007952B1 (da)
ES (1) ES2286304T3 (da)
FR (1) FR2831446B1 (da)
HU (1) HUP0401633A3 (da)
IL (2) IL161116A0 (da)
IS (1) IS2849B (da)
MX (1) MXPA04003910A (da)
NO (1) NO332313B1 (da)
NZ (1) NZ532130A (da)
PL (1) PL209263B1 (da)
PT (1) PT1441723E (da)
WO (1) WO2003035062A1 (da)
ZA (1) ZA200402696B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TR200301553A1 (tr) * 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
WO2006067601A1 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of irbesartan and hydrochlorothiazide and processes for their preparation
CN100367959C (zh) * 2006-08-29 2008-02-13 陈俊云 一种含有依贝沙坦的药物
GB0617171D0 (en) * 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
EP4313024A1 (en) * 2021-03-23 2024-02-07 Dimerix Bioscience Pty Ltd Treatment of inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
TW201738B (da) * 1990-03-20 1993-03-11 Sanofi Co
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5292741A (en) * 1992-08-18 1994-03-08 Merck & Co., Inc. Macrocycles incorporating quinazolinones
US20020068740A1 (en) 1999-12-07 2002-06-06 Mylari Banavara L. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications

Also Published As

Publication number Publication date
NZ532130A (en) 2006-10-27
HUP0401633A2 (hu) 2004-12-28
US8088827B2 (en) 2012-01-03
NO332313B1 (no) 2012-08-27
PT1441723E (pt) 2007-07-26
FR2831446B1 (fr) 2004-03-05
ZA200402696B (en) 2005-06-29
PL368737A1 (en) 2005-04-04
CY1106746T1 (el) 2012-05-23
IS7200A (is) 2004-03-29
CA2461625A1 (en) 2003-05-01
WO2003035062A1 (fr) 2003-05-01
CN1610548A (zh) 2005-04-27
IL161116A (en) 2010-12-30
CN100418526C (zh) 2008-09-17
PL209263B1 (pl) 2011-08-31
EA200400438A1 (ru) 2004-10-28
FR2831446A1 (fr) 2003-05-02
CA2461625C (en) 2011-07-05
JP2005506369A (ja) 2005-03-03
US20090247510A1 (en) 2009-10-01
IL161116A0 (en) 2004-08-31
EA007952B1 (ru) 2007-02-27
AU2002350832B2 (en) 2006-11-30
ATE361071T1 (de) 2007-05-15
DE60219940T2 (de) 2008-01-17
MXPA04003910A (es) 2004-07-23
JP4542777B2 (ja) 2010-09-15
EP1441723A1 (fr) 2004-08-04
IS2849B (is) 2013-09-15
EP1441723B1 (fr) 2007-05-02
ES2286304T3 (es) 2007-12-01
BR0213479A (pt) 2004-11-03
DE60219940D1 (de) 2007-06-14
US20040242567A1 (en) 2004-12-02
NO20041732L (no) 2004-07-23
HUP0401633A3 (en) 2009-06-29

Similar Documents

Publication Publication Date Title
NO20071343L (no) Substituerte fenylaminotiazoler og anvendelse derav
NO20062767L (no) Immunoglobuliner
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
NO20052626D0 (no) Middel for forhindring eller behandling av neuropati
NO20052739L (no) CCR5-antagonister som medikamenter
IS2855B (is) 4-anilínókínasólínafleiður sem andfjölgunarefni
NO20075074L (no) Kinazolinon T-type-kalsiumkanalantagonister
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
ATE551059T1 (de) Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
EE200300475A (et) Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
ATE405269T1 (de) Cyclohexylverbindungen als ccr5-antagonisten
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
DK1556021T3 (da) Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger
NO20030411D0 (no) Farmasöytiske sammensetninger for behandlingen av smertefulle, inflammatoriske og ulceröse tilstander av fuktige epiteloverflater slik sommukositt, stomatitt og Behcets syndrom
DE60322423D1 (de) Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten
CY1106746T1 (el) Χρηση του irbesartan για την προληψη ή τη θεραπεια της πνευμονικης υπερτασης
NO20076405L (no) Anvendelse av 24-nor-UDCA
DK1843771T3 (da) Anvendelse af pyrimidylaminobenzamider til behandling af sygdomme, der responderer på modulation af Tie-2-kinase-aktiviteten
CY1110043T1 (el) 2-αμινοβενζουλ παραγωγα
AU2002350832A1 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
WO2004055001A3 (en) Rabeprazole calcium
DK1503764T3 (da) 5-HT4-receptor-antagonister til behandling af hjertesvigt
DK1425007T3 (da) Anvendelse af C2-substituerede indan-1-ol-systemer til fremstilling af medikamenter til profylaxe eller behandling af obesitas
DK1490049T3 (da) Citalopram til behandling af forhöjet blodtryk
SI1441723T1 (sl) Uporaba irbesartana za preprečevanje ali zdravljenje pljučne hipertenzije